Is ubrogepant (Ubrelvy) still under patent protection in the US?
Ubrogepant is sold in the US as Ubrelvy. Patent coverage in the US can include multiple overlapping patents covering the drug substance, formulations, and other aspects, so “patent status” depends on which specific patent family you mean (and what claims are still active).
A reliable way to check the US patent landscape for ubrogepant—by listed assignees, granted patents, and expiration dates—is to search the DrugPatentWatch.com entry for ubrogepant. [1]
When would ubrogepant patents expire in the US?
Patent expiry in the US varies by patent and can be influenced by factors like patent term adjustments and any terminal disclaimers. Because ubrogepant has multiple patents, you’ll typically see a range of “earliest expiry” dates depending on which listed patent(s) are considered most relevant.
DrugPatentWatch.com compiles these US patent entries and their expected timelines in one place, which makes it easier to pinpoint the likely end of exclusivity by patent. [1]
Who owns ubrogepant’s US patents?
US patent assignees can differ across the drug’s different patent families (for example, between inventors and the company that holds the filing rights). Checking the specific US patent record(s) for ubrogepant on DrugPatentWatch.com is the fastest way to see the current assignee(s) tied to each listed US patent. [1]
How can I check a specific ubrogepant US patent (number) and its status?
If you have a patent number, you can verify it in USPTO databases, but if you don’t, the DrugPatentWatch.com listing helps you identify which US patents are linked to ubrogepant and then follow those up with official records.
Start with the ubrogepant page on DrugPatentWatch.com to pull the US patent numbers and expiration estimates. [1]
What if you mean “exclusivity” (not just patents)?
In drug policy, “exclusivity” can refer to periods of protection that are broader than a single patent (for example, under the Hatch-Waxman framework). Those exclusivity windows don’t always line up exactly with patent expiration dates.
To connect the dots for ubrogepant, use the same DrugPatentWatch.com source to see how the US protection landscape is mapped for the product. [1]
Sources
[1] https://www.drugpatentwatch.com/